Jason G. Harb

AbbVie (United States) — United States

Medicine · Health Sciences

16h-index1.9kcitations75works4.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Myeloid Leukemia Treatments(40), Acute Myeloid Leukemia Research(37), Myeloproliferative Neoplasms: Diagnosis and Treatment(19), Immune Cell Function and Interaction(12), MicroRNA in disease regulation(9)

Publications75 total

CLO25-058: First-in-Human, Multicenter Phase 1 Study of the Bromodomain 2 Inhibitor ABBV-744 in Relapsed/Refractory Acute Myeloid Leukemia
Journal of the National Comprehensive Cancer Network·2025
Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response
Blood Neoplasia·2024· 8 citedOpen Access
New era for myelofibrosis treatment with novel agents beyond Janus kinase‐inhibitor monotherapy: Focus on clinical development of BCL‐X<sub>L</sub>/BCL‐2 inhibition with navitoclax
Cancer·2023· 15 citedOpen Access
Supplementary Figure 5 from Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on &lt;i&gt;MIR300&lt;/i&gt; Antiproliferative and PP2A-Activating Functions
2023Open Access
Supplementary Figure 5 from Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on &lt;i&gt;MIR300&lt;/i&gt; Antiproliferative and PP2A-Activating Functions
2023Open Access
Supplementary Figure 2 from Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on &lt;i&gt;MIR300&lt;/i&gt; Antiproliferative and PP2A-Activating Functions
2023Open Access
Table S1 from Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on &lt;i&gt;MIR300&lt;/i&gt; Antiproliferative and PP2A-Activating Functions
2023Open Access
Supplementary Figure 1 from Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on &lt;i&gt;MIR300&lt;/i&gt; Antiproliferative and PP2A-Activating Functions
2023Open Access
Supplementary Figure 3 from Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on &lt;i&gt;MIR300&lt;/i&gt; Antiproliferative and PP2A-Activating Functions
2023Open Access
Supplementary Figure 6 from Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on &lt;i&gt;MIR300&lt;/i&gt; Antiproliferative and PP2A-Activating Functions
2023Open Access
Supplementary Figure 7 from Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on &lt;i&gt;MIR300&lt;/i&gt; Antiproliferative and PP2A-Activating Functions
2023Open Access
Supplementary Figure 1 from Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on &lt;i&gt;MIR300&lt;/i&gt; Antiproliferative and PP2A-Activating Functions
2023Open Access
Supplementary Figure 7 from Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on &lt;i&gt;MIR300&lt;/i&gt; Antiproliferative and PP2A-Activating Functions
2023Open Access
Supplementary Figure 2 from Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on &lt;i&gt;MIR300&lt;/i&gt; Antiproliferative and PP2A-Activating Functions
2023Open Access
Data from Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on &lt;i&gt;MIR300&lt;/i&gt; Antiproliferative and PP2A-Activating Functions
2023Open Access
Supplementary Figure 4 from Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on &lt;i&gt;MIR300&lt;/i&gt; Antiproliferative and PP2A-Activating Functions
2023Open Access
Supplementary Figure 3 from Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on &lt;i&gt;MIR300&lt;/i&gt; Antiproliferative and PP2A-Activating Functions
2023Open Access
Supplementary Figure 4 from Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on &lt;i&gt;MIR300&lt;/i&gt; Antiproliferative and PP2A-Activating Functions
2023Open Access
Table S1 from Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on &lt;i&gt;MIR300&lt;/i&gt; Antiproliferative and PP2A-Activating Functions
2023Open Access
Data from Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on &lt;i&gt;MIR300&lt;/i&gt; Antiproliferative and PP2A-Activating Functions
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Danilo Perrotti(29), Paolo Neviani(26), Guido Marcucci(26), Peter Hokland(17), Christopher J. Walker(17), Justin J. Ellis(15), Joshua J. Oaks(14), Ramiro Garzon(14), Denis‐Claude Roy(14), Ramasamy Santhanam(13), Dragana Milojković(13), Jane F. Apperley(13), Alistair Reid(13), Jacqueline S. Garcia(12), Maria R. Baer(12), Claudia S. Huettner(11), Rossana Trotta(11), Catriona Jamieson(11), Carlo Gambacorti‐Passerini(11), Philippa C. May(10)